TY - JOUR
T1 - Neural correlates of subjective cognitive decline in adults at high risk for Alzheimer’s disease
AU - Ben-Ami, Liat
AU - Ravona-Springer, Ramit
AU - Tsarfaty, Galia
AU - Raizman, Reut
AU - Shumacher, Aleeza
AU - Sharvit-Ginon, Inbal
AU - Greenbaum, Lior
AU - Bendlin, Barbara B.
AU - Okun, Eitan
AU - Heymann, Anthony
AU - Schnaider Beeri, Michal
AU - Livny, Abigail
N1 - Publisher Copyright:
Copyright © 2023 Ben-Ami, Ravona-Springer, Tsarfaty, Raizman, Shumacher, Sharvit-Ginon, Greenbaum, Bendlin, Okun, Heymann, Schnaider Beeri and Livny.
PY - 2023/2/1
Y1 - 2023/2/1
N2 - Introduction: Recently, interest has emerged in subjective cognitive decline (SCD) as a potential precursor to Alzheimer’s disease (AD) dementia. Whether individuals with SCD harbor brain alterations in midlife, when AD-related pathology begins, is yet to be elucidated. Furthermore, the role of apolipoprotein ε4 (APOE ε4) allele, a robust AD risk factor, in the relationship between SCD and brain alterations is unknown. We examined whether APOE genotype modulates the association of SCD with brain measures in individuals at high AD risk. Methods: Middle-aged adults with parental history of AD dementia underwent magnetic resonance imaging (MRI) and the Memory Functioning Questionnaire. Regression analysis tested the extent to which SCD was associated with activation during an functional MRI (fMRI) working-memory task, and white-matter microstructure. APOE ε4 genotype was tested as a moderator. Results: Among APOE ε4 carriers, but not among non-carriers, SCD was associated with higher activation in the anterior cingulate (p = 0.003), inferior, middle, and superior frontal cortices (p = 0.041, p = 0.048, p = 0.037, respectively); and with lower fractional anisotropy in the uncinate fasciculus (p = 0.002), adjusting for age, sex, and education. Conclusion: In middle aged, cognitively normal individuals at high AD risk, higher SCD was associated with greater brain alterations possibly reflecting incipient AD pathology. When accompanied by a family history of AD and an APOE ε4 allele, SCD may have important clinical value, allowing a window for early intervention and for participants’ stratification in AD prevention clinical trials.
AB - Introduction: Recently, interest has emerged in subjective cognitive decline (SCD) as a potential precursor to Alzheimer’s disease (AD) dementia. Whether individuals with SCD harbor brain alterations in midlife, when AD-related pathology begins, is yet to be elucidated. Furthermore, the role of apolipoprotein ε4 (APOE ε4) allele, a robust AD risk factor, in the relationship between SCD and brain alterations is unknown. We examined whether APOE genotype modulates the association of SCD with brain measures in individuals at high AD risk. Methods: Middle-aged adults with parental history of AD dementia underwent magnetic resonance imaging (MRI) and the Memory Functioning Questionnaire. Regression analysis tested the extent to which SCD was associated with activation during an functional MRI (fMRI) working-memory task, and white-matter microstructure. APOE ε4 genotype was tested as a moderator. Results: Among APOE ε4 carriers, but not among non-carriers, SCD was associated with higher activation in the anterior cingulate (p = 0.003), inferior, middle, and superior frontal cortices (p = 0.041, p = 0.048, p = 0.037, respectively); and with lower fractional anisotropy in the uncinate fasciculus (p = 0.002), adjusting for age, sex, and education. Conclusion: In middle aged, cognitively normal individuals at high AD risk, higher SCD was associated with greater brain alterations possibly reflecting incipient AD pathology. When accompanied by a family history of AD and an APOE ε4 allele, SCD may have important clinical value, allowing a window for early intervention and for participants’ stratification in AD prevention clinical trials.
KW - APOE
KW - Alzheimer’s dementia (AD)
KW - diffusion tensor imaging
KW - fMRI
KW - family history (FH)
KW - neuroimaging
KW - subjective cognitive decline (SCD)
KW - working memory
UR - http://www.scopus.com/inward/record.url?scp=85148348575&partnerID=8YFLogxK
U2 - 10.3389/fnagi.2023.1067196
DO - 10.3389/fnagi.2023.1067196
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 36819726
AN - SCOPUS:85148348575
SN - 1663-4365
VL - 15
JO - Frontiers in Aging Neuroscience
JF - Frontiers in Aging Neuroscience
M1 - 1067196
ER -